Editors: Olli Kallioniemi, William Hennah, Mari Kaunisto, Marja Medina, Reetta Niemelä, Gretchen Repasky, Susanna Rosas, Jouko Siro, Tiina Vesterinen
|
|
- Abel Long
- 8 years ago
- Views:
Transcription
1 ANNUAL REPORT 2012
2 Editors: Olli Kallioniemi, William Hennah, Mari Kaunisto, Marja Medina, Reetta Niemelä, Gretchen Repasky, Susanna Rosas, Jouko Siro, Tiina Vesterinen Photos and graphics: Jouko Siro, Masha Anastasina, Lise Balsby, Sami Blom, Jason DeBose, Oxana Denisova, Henrik Edgren, Samuel Eldfors, Caroline Heckman, William Hennah, Wilma Hurskainen, Harri Itkonen, Mari Kaunisto, Siv Knaappila, Sergey Kuznetsov, Kari Likonen, Michel Mees, Muntasir Mamun Majumder, Ruusu-Maaria Merivirta, Timo Miettinen, John Patrick Mpindi, Katja Närhi, Tea Pemovska, Aleksi Poutanen, Maija Puhka, Gretchen Repasky, Mikko Sallinen, Veikko Somerpuro, Rauno Träskelin, Tiina Vesterinen Academy of Finland, EATRIS, European Molecular Biology Laboratory (EMBL), Finnish Red Cross Blood Service and University of Helsinki are acknowledged for the photos. Juvenes Print 2013
3 Contents Director s overview... 4 The first five years at FIMM... 6 Nordic EMBL Partnership for Molecular Medicine expanded to Denmark... 8 Greetings... 9 Bridge-building towards the clinic... 9 Chair of the Board of FIMM...10 Former Chair of the Board of FIMM, Vice President for Research, Academy of Finland...10 Chancellor of the University of Helsinki...11 Grand Challenges Individualized Systems Medicine (ISM) for accelerating translational oncology in AML...12 Utilizing Finnish Genomes to empower personalised and predictive health...13 Research Highlights Research Groups in Human Genomics Group Palotie...19 Group Hennah...21 Group Palmgren...22 Group Ripatti...23 Group Saarela...24 Group Widen...25 Research Groups in Systems Medicine and Translational Research Group Kallioniemi...26 Group Aittokallio...27 Group Kainov...28 Group Knowles...29 Group Kuznetsov...30 Group Lundin...31 Group Verschuren...33 Group Wennerberg...34 Finland Distinguished Professors at FIMM Doctoral Training Technology Centre Biobanking Administration Examples of On-going Projects A year at FIMM FIMM in Figures Publications FIMM 3
4 Director s overview When starting as the Director of FIMM in December 2007, I was asked to prepare a plan for the development of the new institute as part of the Nordic EMBL Partnership for Molecular Medicine. The following is an excerpt from these plans: Molecular medicine of the future needs to focus on personalised medicine, making use of molecular data at the level of the individual patient to drive diagnostic and therapeutic decisions. FIMM represents a unique opportunity to advance molecular medicine in Finland. The focus and mission should revolve around translational research, i.e. taking advantage of the high-quality biomedical discoveries in Finland to advance personalised medicine in the decades to come. Everything above is still very true as we now venture towards the next 5-year period. However, as compared to the 2007, we now have almost 200 people, 15 group leaders, a strong Technology Centre and Biobanking Infrastructure to help realize such goals. Significant progress towards scientific breakthroughs and personalised medicine has happened and much more is now underway. Photo by Michel Mees EATRIS is credited for the photo. FIMM was awarded an excellent start-up funding to recruit EMBL-style group leaders and to launch a new institute. The support from Jane and Aatos Erkko Foundation, Sigrid Jusélius Foundation, The Finnish Medical Foundation, Orion- Farmos Research Foundation, the City of Helsinki, Ministry of Education and Culture, the University of Helsinki and the Hospital District of Helsinki and Uusimaa (HUS) is gratefully acknowledged. This annual report is a testimony to what has been achieved in the past five years. The start-up funding helped to build an institute and recruit an excellent group of young talented investigators at all levels, from PIs to PhD students. Due to everybody s dedicated work, FIMM is now established in the international arena as an expert site for human genomics and personalised medicine research, with groundbreaking translational and clinical capabilities. The FIMM start-up funding is now ending in As a result of the University Reform Act in 2009, the future of FIMM will remain largely dependent on the basic funding support from its primary host, the University of Helsinki. Since the budgets for universities are not increasing, it is very difficult for the University to assume responsibility for all the work previously supported by the start-up funds at FIMM. Therefore, most likely the total support for FIMM research will go down in Fortunately, FIMM has acquired significant external project funding from diverse sources, about 10 M /year in The science policy in Finland is designed such that the research community is dependent on a continuous supply of competitive external grants. While FIMM researchers have been very successful in acquiring such funding, this will not serve as a replacement for basic funding. Therefore, our ability to operate an EMBL-style molecular medicine institute with rotating group leader positions is far from certain in this scenario. Like any other institute under the University of Helsinki umbrella, FIMM has to rely largely on competitive national and international project funding for its support. This is not quite like the EMBL model, where recruitment of international top talent to rotational 5+4 year PI-positions with good basic support is a key feature. Also, term-limited grant support is not optimal for running long-term highrisk and ambitious research goals of societal importance. With these challenges on the future in mind, what is the FIMM strategy for the future? We remain committed to carry out high-quality research and to translate these to the clinic. We believe that an important way to achieve this will be to focus strongly on grand challenges in the society, and make almost the entire institute to work together towards such goals. We have two established and one emerging grand challenge initiatives under development at FIMM. The first one involves the application of Finnish ge- 4 FIMM
5 nome information for the development of personalised and predictive health care. The second one involves the development of the concept of individualized systems medicine for cancer care, starting from acute leukaemias. The third grand challenge involves digital image-based pathological diagnostics, which will be required as we move molecular pathology towards multiplexed in situ assays, quantitative assays and automatic decision support. Taken together, we believe that these three grand challenges will help to refine the institutes mission. In 2020, we hope to have contributed to a national policy that enables Finland to be a leading country in the implementation of personalised medicine in health care at the level of the citizens, primary care, secondary care, both public and private. Professor Olli Kallioniemi, Director, FIMM Orion-Farmos Research Foundation FIMM 5
6 The first five years at FIMM Janna Saarela appointed Research Director, FIMM Technology Centre 200 Personnel FIMM-EMBL Group Leaders Emmy Verschuren and Denis Kainov FIMM National Network for Molecular Medicine 150 First FIMM-EMBL Group Leader Sergey Kuznetsov EATRIS project ENGAGE project : The idea to establish an international molecular medicine research centre in the Nordic countries. Academy Professor Olli Kallioniemi appointed first Director of FIMM Academy Professor Leena Peltonen-Palotie appointed Research Director of FIMM Human Genomics Initiative of the Academy of Finland to establish a research centre in Finland with EMBL Report of the Biotechnology 2005 Expert Group of the Ministry of Education Decision on the establishment of FIMM by the Senate of the University of Helsinki as a joint institute of the University, HUS and KTL Finnish Genome Centre merged to FIMM VTT joined FIMM Biomedicum Helsinki 2U building The Board and SAB of FIMM nominated Start-up funding from the Ministry of Education ( ), Erkko, Jusélius, Finnish Medical and Orion-Farmos Foundations, the City of Helsinki and HUS THL established (KTL and Stakes merged) 6 FIMM Establishment of the Nordic EMBL Partnership for Molecular Medicine
7 FiDiPro Professor Jonathan Knowles FIMM-EMBL Group Leaders Krister Wennerberg and Samuli Ripatti FIMM Clinical Collaboration Programme FIMM-EMBL PhD International Training Initiative Biomedinfra (national ESFRI collaboration) PREDECT (Innovative Medicine Initiative) Biocenter Finland funding EU-OPENSCREEN project FiDiPro Professor Juni Palmgren FIMM-EMBL Group Leader Tero Aittokallio Johan Lundin appointed Research Director, Diagnostic Development Olli Kallioniemi appointed Director of FIMM FiDiPro Professor Leif Groop BBMRI-LPC project Aarno Palotie appointed Research Director, FIMM Human Genomics Vision: 2020 FIMM is an international leading centre for molecular medicine and Finland is a leading country in personalised medicine New University Law FIMM Launch Event and SAB Visit The Board of FIMM nominated International Evaluation of Research and Doctoral Training at the University of Helsinki Academician of Science Leena Peltonen-Palotie Memorial Symposium Renewal and expansion of the Nordic EMBL Partnership for Molecular Medicine SAB Visit and FIMM 5-year Evaluation SAB Visit FIMM 7
8 Nordic EMBL Partnership for Molecular Medicine expanded to Denmark The Nordic EMBL Partnership for Molecular Medicine expanded to Denmark as the agreement between EMBL, DANDRITE, Aarhus University, FIMM, University of Helsinki, MIMS, Umeå University and NCMM, University of Oslo was signed on 5 March 2013 in Aarhus, Denmark. The Agreement for Establishing the Nordic EMBL Partnership was initially signed in 2007 for a five-year period. Now the agreement was renewed for a ten-year period. Rector Thomas Wilhelmsson and Director Olli Kallioniemi signed the agreement on behalf of FIMM, University of Helsinki. When establishing the Nordic EMBL Partnership in 2007, the idea was to promote synergistic collaboration between the Nordic countries and EMBL. The Partnership has achieved its goals. stated Director General of EMBL, Professor Iain Mattaj in Aarhus. He also found it important that the collaboration is based on national strengths of the four Nordic countries and that the research focus areas in the nodes are complementary in nature. The Nordic EMBL Partnership provides an excellent platform for Nordic and European research and infrastructure collaboration. In addition, joint training initiatives and mobility of researchers can be supported in many ways within this institutional and coordinated Partnership. said Rector Thomas Wilhelmsson. DANDRITE (Danish Research Institute of Translational Neuroscience) started in January 2013 with three core groups of Professors Poul Nissen (Interim Director), Anders Nykjaer and Poul Henning Jensen. Altogether five EMBL style selected group leaders will be recruited to the Institute. In addition to Aarhus University, the Lundbeck Foundation is committed to fund DANDRITE for a ten-year period. Photos by Lise Balsby 8 FIMM
9 Greetings Bridge-building towards the clinic Cancer diagnostics and treatments have changed substantially during the last several years. No longer are all cancers considered to behave similarly in all patients. Instead, a more precise diagnostic workup is anticipated to reveal different subcategories for different cancer types. All this aims at optimized patient outcome as treatments can be individualized. This personalised approach to cancer diagnostics and treatments is to a large extent driven by a fast development of laboratory technologies. Not only have techniques like next-generation sequencing become cheaper and faster, but also novel and exciting technologies such as high-throughput drug testing and automated image analysis are around the corner. To eventually utilize these techniques in patient care, thorough translational research needs to be conducted. In this respect, the natural collaborator for a clinician in Helsinki University Central Hospital (HUCH) is FIMM, with its impressive infrastructure and innovative research groups. A good example of successful collaboration is individualized treatment of Acute Myeloid Leukaemia (AML) patients using Drug Sensitivity and Resistance Testing (DSRT) technology in a joint program between Division of Hematology at HUCH and FIMM. This programme is backed up by an ambitious national biobanking protocol set up between the Finnish Association of Hematology and FIMM ( A similar approach is used for urologic solid organ tumours, also backed up by a collaborative biobanking protocol between Department of Urology at HUCH and FIMM with impressive 600 patient consents and more that sample aliquots collected after the first year of operation only ( Professor Kimmo Porkka and Docent Antti Rannikko, University of Helsinki and Helsinki University Central Hospital (HUCH) FIMM 9
10 Chair of the Board of FIMM The year 2012 concluded the five-year ( ) start-up and construction phase of FIMM. During this period, FIMM has become an international high-profile research institute in molecular medicine research, with world-class infrastructure, focus towards creating tangible benefits to the society and applications linking top-class medical research with industrial collaboration. The results of the International Evaluation of Research and Doctoral Training of the University of Helsinki were published in FIMM researchers were involved in three Researcher Communities: Cancer Biology (CANBIO), Complex Disease Genomics Group (CompDisGen) and Personalised Molecular Medicine (P-Molmed). All of these received top scores, with the P-Molmed receiving the highest ranking score in the category for societal impact. In 2012, based on the recommendations of the Scientific Advisory Board (SAB) and Board of FIMM, Rector Thomas Wilhelmsson appointed Professor Olli Kallioniemi the Director of FIMM for another five-year term, starting in December Olli Kallioniemi s Inauguration Lecture Personalised Medicine 2020 took place in January Together with Rector Thomas Wilhelmsson and the Board of FIMM, we have carefully discussed the FIMM funding situation in the forthcoming years. International recruitment of global experts to Finland has been implemented with internationally competitive support packages (about 1.5 M /group leader/five years) during the first five-year period, by virtue of valuable support from several private foundations and the University of Helsinki. FIMM researchers have been successful in competition of external project funding. However, maintenance of EMBL group leader salaries and attractive long-term start-up packages cannot be covered by external project funding only. Acquisition of sustainable funding to maintain the EMBL status remains a challenging, but reachable, task in the future. Professor Kimmo Kontula, Vice Rector of the University of Helsinki, Chair of the Board of FIMM Former Chair of the Board of FIMM, Vice President for Research, Academy of Finland The European Molecular Biology Laboratory (EMBL) was founded in 1974 as an intergovernmental institute to initiate in Europe research in the then new field, molecular biology. Today, EMBL is one of the world s leading institutes in the life sciences, funded by 20 Member States and operating in its headquarters in Heidelberg and four outstations, embracing four partnerships. One of the latter is the Nordic EMBL Partnership for Molecular Medicine, established in 2007, between EMBL, the Institute for Molecular Medicine Finland (FIMM) in Helsinki, the Centre for Molecular Medicine Norway (NCMM) in Oslo and the Laboratory for Molecular Infection Medicine Sweden (MIMS) in Umeå. The high quality health care systems, population-based registers, and patient and sample databases in the Nordic countries provide the unique niche for this collaboration. In March 2013, the Nordic EMBL Partnership was extended by a most welcome new member, the Danish Research Institute of Translational Neuroscience (DANDRITE) in Aarhus. The strengthening of the Nordic EMBL Partnership could not be timelier, as the Nordic Council of Ministers is in the process of considering opening up of research and funding opportunities and access to infrastructure across the borders of Denmark, Finland, Iceland, Norway and Sweden. The Nordic EMBL Partnership is optimally placed to further and take advantage of collaboration not only in the Nordic countries, but also to bridge it with research activities, funding opportunities and infrastructure at the European level. Professor Marja Makarow, Vice President for Research, Academy of Finland (Vice Rector of the University of Helsinki ; Chief Executive of the European Science Foundation ; Chair of the Board of FIMM ) 10 FIMM
11 Chancellor of the University of Helsinki In spring 2006, the Ministry of Education and Culture (then, the Ministry of Education) commissioned the University of Helsinki to begin preparatory work to establish a research institute for molecular medicine as a joint undertaking with other biocentre universities, as well as with other institutions in the field. Background for the assignment was the initiative of an expert group of the Academy of Finland and the Biotechnology 2005 committee report of the Ministry of Education. After some negotiations, the other biocentre universities decided not to join to the institute. As the Rector of the University of Helsinki, I chaired the University Senate meeting in autumn 2006 which decided to establish the Institute for Molecular Medicine Finland (FIMM) as a joint effort of the University, the Hospital District of Helsinki and Uusimaa (HUS), and the National Institute for Health and Welfare (THL, then the National Public Health Institute, KTL). VTT Technical Research Centre of Finland joined FIMM in The Agreement for Establishing the Nordic EMBL Partnership for Molecular Medicine was signed in Heidelberg in Today, I am happy to see that only five years after its establishment, FIMM is a highly successful international institute with a clearly defined profile in basic and translational research, with highly qualified doctoral students, researchers, group leaders and Finland Distinguished Professors, and with a world-class research infrastructure and nation-wide and international technology services. FIMM has fully accomplished the objectives set in the reports initiating the establishment of the institute. Professor Ilkka Niiniluoto, Chancellor of the University of Helsinki (Rector of the University of Helsinki ) EMBL signing ceremony in EMBL is credited for the photo. FIMM 11
12 Grand Challenges Individualized Systems Medicine (ISM) for accelerating translational oncology in AML We have established a close collaboration with hematologists at the Helsinki University Central Hospital (HUCH) to develop a novel Individualized Systems Medicine (ISM) strategy for translational cancer research. We combine biobanking, state-of-the-art genomic technology, high-throughput drug testing, and rapid clinical translation in a programme that has grown into a major effort at FIMM and HUCH. We selected adult Acute Myeloid Leukaemia (AML) as the primary target of our studies due to its lower complexity as compared to solid tumours. Millions of cells can be readily obtained for both molecular and ex vivo drug response studies. Sampling at the time of diagnosis, remission and relapse and drug resistance is easily accomplished. Indeed, analysis of temporal evolution patterns in individual patients represents the unique opportunity. AML patients, particularly those with treatment-refractory disease with less than 10% long-term survival expectation, desperately need new therapeutic options to replace the year-old chemotherapeutic regimens. Refractory AML therefore represents an ideal indication to introduce individualized treatments to improve cancer care. ISM combines multiple levels of medical, technological, scientific, and strategic aspects to practice translational cancer medicine as follows: Focus on individual patients: We will seek to understand and interpret the unique genomic and molecular profile of the disease in each individual patient. Direct prediction of response to all drugs: Functional, large-scale drug response data are acquired from ex vivo primary culture of cancer cells from patients. Real-time science: Biobanking, profiling, analysis, and interpretation of each case in 1 4 weeks, with feedback to the clinician. Scientists work in parallel with clinical developments one case at-a-time. Consecutive sampling from different stages of cancer evolution: Understanding of mechanisms of drug resistance and cancer evolution for each patient. Integration of in vivo, ex vivo and in vitro data: Model systems will be designed to understand mechanisms and causalities, such as drug combinations, based on ex vivo data from patient samples. Thus patient samples and models are compared to one another. Implementation: Patient consent and ethical permission allow implementation of actionable results in the clinic at a time when no other therapy options exist. Drug combinations: We will identify synergistic drug regimens blocking multiple cancer subclones and escape routes for cancer cells. Systems medicine strategy: Continuous circle of (re)analysis of data and improving models and understanding: learning from each patient and each consecutive sample. De-risking clinical trials: ISM is likely to help choose the right patients and new drugs for clinical trials. 12 FIMM
13 Utilizing Finnish genomes to empower personalised and predictive health The Human Genomics Programme at FIMM builds on a long Finnish tradition of high-impact genetic research. Finland was one of the first countries to embrace advances of molecular genetics already in the 1990s, leading to the identification of mutations causing the Finnish disease heritage. More recently, during the past three years, FIMM researchers have with 44 publications in top medical journals, e.g. Science, Nature, Nature Genetics, Lancet, importantly contributed to the recent discoveries of novel genes and gene loci that underlie common disease. Right now, the rapidly increasing capacity to describe the complete genetic and molecular makeup of an individual is changing the way we understand and treat disease. We foresee that Finland has a unique opportunity to be at the forefront of this developing field. To meet this upcoming grand challenge and opening, our strategy is to work towards building a platform that integrates genomic and health outcome data from Finnish national population biobanks into a globally unique and valuable big data repository. This plan relies on a close collaboration between FIMM and THL, but also on extensive multidisciplinary collaborations with other national stakeholders, e.g. VTT, the University of Eastern Finland, the Health & Technology Center in Oulu, the Finnish Medical Society Duodecim, the City of Helsinki and Kymenlaakso Social and Health Services and international cutting edge scientists and institutions, such as the Wellcome Trust Sanger Institute, Broad Institute and UCLA. We envision that data mining of such a massive health data resource will facilitate predictive and preventive approaches, catalyze innovations in health care, as well as empower individuals to reach out towards better health. In our vision, patients and people are seen as active participants and drivers of a health care system 2.0. FIMM 13
14 Research Highlights Mutation in the STAT3 gene identified as the cause for LGL leukaemia Large granular lymphocytic (LGL) leukaemia is a relatively rare, malignant blood disease of the mature T-cells and, in many cases, it is related to autoimmune diseases such as rheumatoid arthritis. The pathogenetic mechanism of the disease has been unknown. Utilizing the latest DNA sequencing methods that can examine the entire genome, the research groups investigated if the LGL leukaemia cells carry mutations that would explain the onset of the disease. It was discovered that patients suffering from LGL leukaemia have a mutation in the STAT3 gene in a very restricted SH2 area, which has a key effect on the function of the gene. In the future, this result can be utilized in diagnosing the disease and possibly also in treatment, since the first STAT3 inhibitors are already undergoing early clinical trials. The cooperation project of the Meilahti campus research groups was led by Satu Mustjoki, Adjunct Professor (University of Helsinki/HUCH), together with FIMM s researchers Caroline Heckman, Ph.D., and Olli Kallioniemi, Professor, in addition to Kimmo Porkka, Professor, Chief Physician at the Division of Hematology (HUCH). Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP Jr, Heckman CA, Maciejewski JP, Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med May 17;366(20): A Multi-Omic Study Highlights the Link between Inflammation and Low HDL-C We have performed the first genome-wide association analysis on low HDL-C. By combining genomic data with adipose tissue transcriptome and HDL particle lipidome analyses, we provide important insights into HDL biology. We show that genetic variants within inflammatory pathways are associated with low HDL-C. These variants also regulate both adipose tissue and vascular inflammation, suggesting a genetic link between inflammation and low HDL-C. We also demonstrate that not only the quantity but also the quality differs in HDL particles between subjects with low and high HDL-C; antioxidative lipid species are less abundant in HDL particles of subjects with low HDL-C highlighting the importance of distinguishing HDL particles from HDL-cholesterol when relating HDL with cardiovascular risk and atherosclerosis. Importantly, we show the value of using extreme phenotypes in genetic analysis: there are genes, especially in the HLA region, which are not associated with HDL-C in general, but only with extreme HDL-C phenotypes. This observation suggests the presence of low/high HDL-C genes in addition to the HDL-C genes that have been reported in population-based GWA studies. This paper was selected the publication of the week by the Faculty of Medicine, University of Helsinki. Laurila PP, Surakka I, Sarin AP, Yetukuri L, Hyötyläinen T, Söderlund S, Naukkarinen J, Tang J, Kettunen J, Mirel DB, Soronen J, Lehtimäki T, Ruokonen A, Ehnholm C, Eriksson JG, Salomaa V, Jula A, Raitakari OT, Järvelin MR, Palotie A, Peltonen L, Oresic M, Jauhiainen M, Taskinen MR, Ripatti S. Genomic, Transcriptomic, and Lipidomic Profiling Highlights the Role of Inflammation in Individuals With Low High-density Lipoprotein Cholesterol. Arterioscler Thromb Vasc Biol Feb 14. [Epub ahead of print] PubMed PMID: FIMM
15 A quantitative tool for strand-specific mrna expression analysis Primer-independent cdna synthesis during reverse transcription hinders quantitative analysis of bidirectional mrna in eukaryotes as well as in cells infected with RNA viruses. We have developed a simple RT-PCR-based assay for strand-specific geneexpression analysis. By modifying the cdna sequence during reverse transcription, using specially designed primers, the opposite strands of target sequences can be simultaneously detected by postamplification melting curve analysis and primerinitiated transcripts are readily distinguished from nonspecifically primed cdna. We have demonstrated the utility of this technique for analysis of (+) and (-) RNA synthesis of influenza A virus in infected cells. This technique represents a powerful tool for analysis of bidirectional RNA synthesis and it can also be utilized for monitoring primer-independent cdna synthesis during reverse transcription. The technique was highlighted in Biotechniques 2012 year in review as number one of the best PCR methods published in the journal during the year. Feng L, Lintula S, Ho TH, Anastasina M, Paju A, Haglund C, Stenman UH, Hotakainen K, Orpana A, Kainov D, Stenman J. Technique for strand-specific gene-expression analysis and monitoring of primer-independent cdna synthesis in reverse transcription. Biotechniques Apr;52(4): Genome-wide association study reveals genetic loci predisposing to the most common form of migraine By analysing close to 5,000 migraneurs and 7,200 controls by genome-wide association, we identified four gene loci predisposing to the most common form of migraine, migraine without aura. The pathophysiology of migraine is poorly understood. Identification of genes that contribute to the disease susceptibility should improve our understanding of basic disease mechanisms. Freilinger T, Anttila V, de Vries B, Malik R, Kallela M, Terwindt GM, Pozo-Rosich P, Winsvold B, Nyholt DR, van Oosterhout WP, Artto V, Todt U, Hämäläinen E, Fernández-Morales J, Louter MA, Kaunisto MA, Schoenen J, Raitakari O, Lehtimäki T, Vila-Pueyo M, Göbel H, Wichmann E, Sintas C, Uitterlinden AG, Hofman A, Rivadeneira F, Heinze A, Tronvik E, van Duijn CM, Kaprio J, Cormand B, Wessman M, Frants RR, Meitinger T, Müller-Myhsok B, Zwart JA, Färkkilä M, Macaya A, Ferrari MD, Kubisch C, Palotie A, Dichgans M, van den Maagdenberg AM: International Headache Genetics Consortium. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet Jun 10;44(7): The genetics of pubertal growth Growth patterns during puberty correlate with pubertal timing, and variability in pubertal timing associates with health risks later in life, for example for hormonedependent cancers and adverse cardiovascular health. Although there is mounting evidence for these links, few studies have addressed the genetics of distinct phases of childhood growth. With access to over 18,000 study subjects with multiple height measurements from childhood and adolescence within the Early Growth Genetics Consortium, we identified ten loci associated with height growth during the pubertal growth spurt. Among these loci, LIN28B exemplifies a gene which may mediate the link between pubertal development and health risks later in life, as it is a gene known to influence childhood growth, pubertal timing, and cancer progression and prognosis. We also identified a novel growth and pubertal timing locus that influenced expression of the gene MAPK3, also involved in several forms of cancer. Finally, while epidemiological studies suggest that early puberty marks a pathway FIMM 15
16 from rapid prepubertal growth to reduced final height and adult obesity, we show that this is not always the case for individual genetic variants. Our study shows that tracking the genetic effects of individual genes across multiple growth periods may help uncover specific pathways linking childhood events to adult outcomes. Cousminer DL, Berry DJ, Timpson NJ, Ang W, Thiering E, Byrne E, Taal HR,Huikari V, Bradfield JP, Kerkhof M, Groen-Blokhuis MM, Kreiner-Møller E,Marinelli M, Holst C, Leinonen JT, Perry JR, Surakka I, Pietiläinen O, Kettunen J, Anttila V, Kaakinen M, Sovio U, Pouta A, Das S, Lagou V, Power C, Prokopenko I, Evans DM, Kemp JP, St Pourcain B, Ring S, Palotie A, Kajantie E, Osmond C, Lehtimäki T, Viikari JS, Kähönen M, Warrington NM, Lye SJ, Palmer LJ, Tiesler CM, Flexeder C, Montgomery GW, Medland SE, Hofman A, Hakonarson H, Guxens M, Bartels M, Salomaa V; The ReproGen Consortium, Murabito J, Kaprio J, Sørensen TI, Ballester F, Bisgaard H, Boomsma DI, Koppelman GH, Grant SF, Jaddoe VW, Martin NG, Heinrich J, Pennell CE, Raitakari O, Eriksson JG, Smith GD, Hyppönen E, Järvelin MR, McCarthy MI, Ripatti S, Widén E; for the Early Growth Genetics (EGG) Consortium. Genome-wide Association and Longitudinal Analyses Reveal Genetic Loci Linking Pubertal Height Growth, Pubertal Timing, and Childhood Adiposity. Hum Mol Genet Feb 27. [Epub ahead of print] Large population cohort studies reveal that saccular intracranial aneurysms and systolic blood pressure share genetic components Some 3% of the general population develop saccular intracranial aneurysms, the rupture of which is a major cause of life threatening subarachnoid haemorrhage. The basic mechanisms of aneurysm formation and their rupturing are poorly understood, but blood pressure is a well-known risk factor. Using well characterized Finnish population cohorts we demonstrate that one aneurysm susceptibility gene locus is associated with systolic blood pressure suggesting that these two traits have shared genetic components, possibly eluting to a shared disease mechanism. Gaál EI, Salo P, Kristiansson K, Rehnström K, Kettunen J, Sarin AP, Niemelä M, Jula A, Raitakari OT, Lehtimäki T, Eriksson JG, Widen E, Günel M, Kurki M, von Und Zu Fraunberg M, Jääskeläinen JE, Hernesniemi J, Järvelin MR, Pouta A; The International Consortium for Blood Pressure Genome-Wide Association Studies (ICBP-GWAS), Newton-Cheh C, Salomaa V, Palotie A, Perola M: Intracranial Aneurysm Risk Locus 5q23.2 Is Associated with Elevated Systolic Blood Pressure. PLoS Genet Mar;8(3):e Harnessing anticancer drugs for the future fight against influenza Influenza viruses cause significant human morbidity and mortality. To treat the infections, different virus-directed drugs have been developed. However, the currently available drugs are targeting viral proteins and due to a high mutation rate the influenza viruses quickly develop resistance to them. For that reason, nextgeneration antiviral drugs should be directed towards the host functions. In this work, we developed a new cell screening method that can be used to identify potential antiinfluenza drugs and identified two novel compounds with anti-influenza activity. The results of this study provide a foundation for development of next-generation antiviral drugs. Furthermore, these identified compounds can be used as chemical tools when studying the molecular mechanisms of virus-host interactions. Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, Yadav B, Aittokallio T, Kaukinen P, Ahola T, Kuivanen S, Vapalahti O, Kantele A, Tynell J, Julkunen I, Kallio-Kokko H, Paavilainen H, Hukkanen V, Elliott RM, De Brabander JK, Saelens X, Kainov DE. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J Biol Chem Oct 12;287(42): FIMM
17 Metabolic signatures of insulin resistance in young adults Insulin resistance is a core defect in the development of type 2 diabetes. Already in young adults, insulin resistance is associated with an adverse lipid profile and increased risk for future diabetes. To elucidate metabolic pathways underlying the pathogenesis of insulin resistance, we comprehensively characterized systemic metabolite profiles in over 7,000 apparently healthy young adults. We identified a diverse metabolic signature with insulin resistance beyond the conventional characteristics of obesity and dyslipidemia. A combination of amino acids, lipids, and intermediates of glycolysis formed sex-specific imprints of insulin resistance on the metabolite profile already in early adulthood. Although genetic evidence did not provide suggest a causal role of the metabolites in the development of insulin resistance, these metabolites may still help to identify individuals at high risk for progression towards future diabetes. Understanding the relation between insulin resistance and the systemic metabolite profile in young, healthy adults may help to promote lifestyle habits for prevention of insulin resistance prior to overt diabetes. Würtz P, Mäkinen VP, Soininen P, Kangas AJ, Tukiainen T, Kettunen J, Savolainen MJ, Tammelin T, Viikari JS, Rönnemaa T, Kähönen M, Lehtimäki T, Ripatti S, Raitakari OT, Järvelin MR, Ala-Korpela M. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes Jun;61(6): New computational strategies combine different omics data and identify susceptibility genes for common traits and help to construct disease networks New methods to analyse large, omics datasets provide opportunities to improve our understanding of disease mechanisms and construct disease networks. We have combined GWAs and expression data in a multivariant model and demonstrate the power of this strategy to improve the analysis of large genome datasets. Inouye M, Ripatti S, Kettunen J, Lyytikäinen LP, Oksala N, Laurila PP, Kangas AJ, Soininen P, Savolainen MJ, Viikari J, Kähönen M, Perola M, Salomaa V, Raitakari O, Lehtimäki T, Taskinen MR, Järvelin MR, Ala-Korpela M, Palotie A, de Bakker PI: Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet Aug;8(8):e FIMM 17
18 Research Groups in Human Genomics Based on the recommendations of the Scientific Advisory Board (SAB) and Board of FIMM Dr. Aarno Palotie was appointed Research Director in the field of Human Genomics in November 2012 (part-time position). Aarno Palotie is a former Director of the Finnish Genome Center. He has been one of the leaders of Human Genomics at FIMM during the last two years, while his main affiliation has been at the Wellcome Trust Sanger Institute in UK. FIMM will increasingly focus on the bioinformatic integration of genomics and other omics data with health care information, as well as on the implementation of genomics in health care. Dr. Palotie is committed to lead these Finnish grand challenge initiatives on genomes and health. In collaboration with our national and international partners, we aim to capitalize on Finland s unique population structure and decades of investments in epidemiological and clinical cohorts. Our goal is to make Finland the poster child of genomic medicine. he said. Dr. Palotie is also hosting FiDiPro Professor Leif Groop s project Using the unique knowledge of the genetics architecture of Finland to identify the genetic variants which explain the inherited risk of diabetes. 18 FIMM
19 Group Palotie Genomics and Health Research Director, Professor Aarno Palotie, MD, PhD The overall aim of our group is to build towards a more comprehensive understanding of the genomic landscape of common diseases utilizing the special opportunities provided by the Finnish population, the Finnish health care infrastructure and large national sample collections. This improved knowledge should provide us with new tools to develop more individualized health care. The recent development of high throughput genotyping and sequencing techniques has made this a realistic goal. The unique setting provided by the Finnish infrastructure has stimulated several large whole exome and whole genome sequencing projects, which have organized themselves in a collaborative initiative called SISu (Sequencing Initiative Suomi). This collaboration includes researchers from FIMM, THL, Lund University, the Broad Institute of MIT and Harvard, Michigan University, UCLA, NIH, Oxford University and the Wellcome Trust Sanger Institute. During 2012, the SISu project has produced the complete genome or exome (coding areas of the genome) sequence of thousands of Finns. When this is combined with the existing genome-wide genotyping (GWA) data from more than 50,000 Finns, we have a rich resource that can be further expanded and used to facilitate a more comprehensive understanding of the genome landscape associated with diseases that are major health burdens to the population. Our group has a special interest in the genetics of neurological and neurodevelopmental traits. Also much of this work draws on the unique clinical and population-based samples collected from the Finnish founder population. These include such clinical collections as the Finnish Migraine Family sample (collected by Dr. Mikko Kallela), the Finnish Schizophrenia family samples (collected by Dr. Jouko Lönnqvist) and the Finnish Autism Sample collection (collected by Dr. Lennart von Wendt) and such population cohorts as the Finrisk, Helsinki Birth Cohort, Northern Finnish Birth Cohort and Health 2000 cohorts ( To combine different fields of expertise and to have sufficient power, these studies are performed in collaboration with several international groups and high throughput platforms. The wealth of multiple large study samples enables the group to use different study designs for genome variant identification and verification and for the estimation of the size of the effect contributed by the variants. These studies include the UK10K study ( and GWAs studies of the International Headache Genetics Consortium chaired by Dr. Palotie Dr. Palotie is a faculty member at the Wellcome Trust Sanger Institute in Cambridge UK and a visiting faculty member at the Broad Institute of MIT and Harvard. Group Members: PI: Aarno Palotie Senior Researcher: Maija Wessman PhD Students: Tiia Luukkonen, Mikko Muona, Olli Pietiläinen Technicians: Eija Hämäläinen, Elli Kempas (until August 2012) Research Nurses: Carita Jussila, Leena Leikas, Anne Nyrhinen Project Coordinator: Sari Kivikko Collaborators in the Helsinki University Central Hospital: Ville Artto, Markus Färkkilä, Mikko Kallela, Salli Vepsäläinen Key publications: Freilinger T, Anttila V, de Vries B, Malik R, Kallela M, Terwindt GM, Pozo-Rosich P, Winsvold B, Nyholt DR, van Oosterhout WP, Artto V, Todt U, Hämäläinen E, Fernández-Morales J, Louter MA, Kaunisto MA, Schoenen J, Raitakari O, Lehtimäki T, Vila-Pueyo M, Göbel H, Wichmann E, Sintas C, Uitterlinden AG, Hofman A, Rivadeneira F, Heinze A, Tronvik E, van Duijn CM, Kaprio J, Cormand B, Wessman M, Frants RR, Meitinger T, Müller-Myhsok B, Zwart JA, Färkkilä M, Macaya A, Ferrari MD, Kubisch C, Palotie A, Dichgans M, van den Maagdenberg AM: International Headache Genetics Consortium. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet Jun 10;44(7): Gaál EI, Salo P, Kristiansson K, Rehnström K, Kettunen J, Sarin AP, Niemelä M, Jula A, Raitakari OT, Lehtimäki T, Eriksson JG, Widen E, Günel M, Kurki M, von Und Zu Fraunberg M, Jääskeläinen JE, Hernesniemi J, Järvelin MR, Pouta A; The International Consortium for Blood Pressure Genome- Wide Association Studies (ICBP-GWAS), Newton-Cheh C, Salomaa V, Palotie A, Perola M: Intracranial Aneurysm Risk Locus 5q23.2 Is Associated with Elevated Systolic Blood Pressure. PLoS Genet Mar;8(3):e FIMM 19
20 Inouye M, Ripatti S, Kettunen J, Lyytikäinen LP, Oksala N, Laurila PP, Kangas AJ, Soininen P, Savolainen MJ, Viikari J, Kähönen M, Perola M, Salomaa V, Raitakari O, Lehtimäki T, Taskinen MR, Järvelin MR, Ala-Korpela M, Palotie A, de Bakker PI: Novel Loci for metabolic networks and multitissue expression studies reveal genes for atherosclerosis. PLoS Genet Aug;8(8):e Kettunen J, Tukiainen T, Sarin A-P, Ortega-Alonso A, Tikkanen E, Lyytikäinen L-P, Kangas AJ, Soininen P, Würtz P, Silander K, Dick DM, Rose RJ, Savolainen MJ, Viikari J, Kähönen M, Lehtimäki T, Pietiläinen KH, Inouye M, McCarthy MI, Jula A, Eriksson J, Raitakari OT, Salomaa V, Kaprio J, Järvelin M-R, Peltonen L, Perola M, Freimer NB, Ala-Korpela M, Palotie A, Ripatti S: Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nature Genetics, Jan 29;44(3):269-76, External research funding: Academy of Finland and Finland Distinguished Professor programme, host for Professor Leif Groop, Helsinki Biomedical Graduate Program (HBGP), Sohlberg Foundation, Sigrid Jusélius Foundation, EU-FP7: SYNSYS, NIH/RFA-HL , Genomic and Metabolomic Profiling of Finnish Familial Dyslipidemia Families 20 FIMM
SEQUENCING INITIATIVE SUOMI (SISU) SYMPOSIUM SPEAKERS August 26, 2014
SEQUENCING INITIATIVE SUOMI (SISU) SYMPOSIUM SPEAKERS August 26, 2014 Professor Aarno Palotie Professor Aarno Palotie is the Research Director of the Human Genomics program at the Finnish Institute for
More informationANNUAL REPORT 2011 www.fimm.fi PL 20, 00014 Helsingin yliopisto Biomedicum Helsinki 2U, Tukholmankatu 8, 00290 Helsinki
ANNUAL REPORT 2011 Contents Overviews and Greetings... 3 Research Groups in Human Genomics... 7 Group Palotie...7 Group Palmgren... 8 Group Ripatti... 9 Group Saarela...10 Group Widén...11 Research Groups
More informationBOARD MEETING 2/2011. 3 May 2011 MINUTES
BOARD MEETING 2/2011 3 May 2011 MINUTES Title: Meeting of the Board of FIMM 2/2011 Time: Tuesday, 3 May 2011, at 14.05 16.10 Place: FIMM Meeting Room D307a, Biomedicum Helsinki 2U (3 rd floor), Tukholmankatu
More informationITT Advanced Medical Technologies - A Programmer's Overview
ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) is a biotechnology company (SME) established in Turkey. Its activity area is research,
More informationHow Can Institutions Foster OMICS Research While Protecting Patients?
IOM Workshop on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials How Can Institutions Foster OMICS Research While Protecting Patients? E. Albert Reece, MD, PhD, MBA Vice
More informationA leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
More informationFINLAND ON A ROAD TOWARDS A MODERN LEGAL BIOBANKING INFRASTRUCTURE
Postrefereed, preprint version of the text published at European Journal of Health Law 2013(3)28994. Link to the publisher s website: http://www.brill.com/europeanjournalhealthlaw Sirpa Soini FINLAND ON
More informationTRACKS GENETIC EPIDEMIOLOGY
Dr. Priya Duggal, Director In the post-genomic era where larger amounts of genetic data are now readily available, it has become increasingly important to design studies and use analytical techniques that
More informationEMBL. International PhD Training. Mikko Taipale, PhD Whitehead Institute/MIT Cambridge, MA USA
EMBL International PhD Training Mikko Taipale, PhD Whitehead Institute/MIT Cambridge, MA USA Why create an EMBL? The structure of DNA had been solved and first protein structures were being identified
More information17th Eemeli Workshop. Wednesday 13th August 2014 VTT, Micronova, Tietotie 3, Espoo. Juhani Luotola, Orion Diagnostica Oy
17th Eemeli Workshop Wednesday 13th August 2014 VTT, Micronova, Tietotie 3, Espoo Juhani Luotola, Orion Diagnostica Oy Juhani Luotola / R&D 13/12/2014 1 2 Personalized Diagnostics and Care Personalized
More informationNational Doctoral Programme in Infections and Antibiotics
Åke Forsberg National Coordinator Anna Holmström National Director of Studies MIMS-affiliated National Doctoral Programme in Infections and Antibiotics (NDPIA) Dept. of Molecular Biology/MIMS Umeå University
More informationBig Data for Population Health
Big Data for Population Health Prof Martin Landray Nuffield Department of Population Health Deputy Director, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery University of Oxford
More informationA Career in Pediatric Hematology-Oncology? Think About It...
A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T
More informationData integration and modelling in health sciences Science as a conversation across borders
Open data key to the future Helsinki 2011-11-01 Data integration and modelling in health sciences Science as a conversation across borders Juni Palmgren Karolinska Institutet and FIMM, Helsinki University
More informationResumen Curricular de los Profesores. Jesse Boehm
Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub
More informationBig Data for Population Health and Personalised Medicine through EMR Linkages
Big Data for Population Health and Personalised Medicine through EMR Linkages Zheng-Ming CHEN Professor of Epidemiology Nuffield Dept. of Population Health, University of Oxford Big Data for Health Policy
More informationInformation for patients and the public and patient information about DNA / Biobanking across Europe
Information for patients and the public and patient information about DNA / Biobanking across Europe BIOBANKING / DNA BANKING SUMMARY: A biobank is a store of human biological material, used for the purposes
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More informationHow To Change Medicine
P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything Leroy E. Hood Institute for Systems Biology David J. Galas Battelle Memorial Institute Version
More informationNEW ALLIANCE FOR EUROPEAN EXCELLENCE AND COMPETITIVENESS IN LIFE SCIENCES
PRESS RELEASE NEW ALLIANCE FOR EUROPEAN EXCELLENCE AND COMPETITIVENESS IN LIFE SCIENCES European research centres in life sciences gather to foster excellence in research, share knowledge, and influence
More informationThe NIH Roadmap: Re-Engineering the Clinical Research Enterprise
NIH BACKGROUNDER National Institutes of Health The NIH Roadmap: Re-Engineering the Clinical Research Enterprise Clinical research is the linchpin of the nation s biomedical research enterprise. Before
More informationThe National Institute of Genomic Medicine (INMEGEN) was
Genome is...... the complete set of genetic information contained within all of the chromosomes of an organism. It defines the particular phenotype of an individual. What is Genomics? The study of the
More informationWorkshop on Establishing a Central Resource of Data from Genome Sequencing Projects
Report on the Workshop on Establishing a Central Resource of Data from Genome Sequencing Projects Background and Goals of the Workshop June 5 6, 2012 The use of genome sequencing in human research is growing
More informationHow can we generate economic value from personalized medicine and big data analysis?
Estonian Health Innovation Forum 2015 Focus on Personalised Medicine How can we generate economic value from personalized medicine and big data analysis? Jonathan Knowles October 26, 2015 Tallinn, Viru
More informationResearch strategy and capacity development in population health science: an MRC and personal view
Research strategy and capacity development in population health science: an MRC and personal view Professor Anne Johnson, UCL Former Chair, MRC Population Health Sciences Strategy Group Foci of MRC and
More informationSUNY UPSTATE MEDICAL UNIVERSITY
Clinical Update May 2007 Major Players: Nurse Practitioners At University Hospital, 120 nurse practitioners make a profound contribution to the quality and scope of services. Page A2 Paving the Way to
More informationDr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
More informationALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
More informationInnovation Platform: Sudden Cardiac Death
Innovation Platform: Sudden Cardiac Death Prof. dr. Bart Loeys CRC Antwerp General Assembly VzW Board of Directors Strategic Advisory Board Staff: 1 executive director 1 ICT manager 1 financial administration
More informationKentucky Lung Cancer Research Program. 2010 Strategic Plan Update
Kentucky Lung Cancer Research Program 2010 Strategic Plan Update Approved by the KLCR Program Governance Board August 12, 2009 KLCR Program Strategic Plan Table of Contents Introduction... 3 GOAL 1: Investigator-Initiated
More informationSchool of Nursing. Presented by Yvette Conley, PhD
Presented by Yvette Conley, PhD What we will cover during this webcast: Briefly discuss the approaches introduced in the paper: Genome Sequencing Genome Wide Association Studies Epigenomics Gene Expression
More informationAcademy of Finland Research Programme SALVE 2009 2012. Responding to Public Health Challenges
Academy of Finland Research Programme SALVE 2009 2012 Responding to Public Health Challenges Responding to Public Health Challenges (SALVE) 2009 2012 SALVE - in brief The Responding to Public Health Challenges
More informationFiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements
Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements PCRP AWARD MECHANISMS WITH EMPHASIS ON RESOURCES Clinical Consortium Award
More informationIf you were diagnosed with cancer today, what would your chances of survival be?
Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. However
More informationClinical Research Infrastructure
Clinical Research Infrastructure Enhancing UK s Clinical Research Capabilities & Technologies At least 150m to establish /develop cutting-edge technological infrastructure, UK wide. to bring into practice
More informationGenetic Testing in Research & Healthcare
We Innovate Healthcare Genetic Testing in Research & Healthcare We Innovate Healthcare Genetic Testing in Research and Healthcare Human genetic testing is a growing science. It is used to study genes
More informationGraduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine
Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine Graduate Certificate in Metabolic & Nutritional Medicine Graduate Certificate Metabolic & Nutritional Medicine Purpose
More informationEuropean Genome-phenome Archive database of human data consented for use in biomedical research at the European Bioinformatics Institute
European Genome-phenome Archive database of human data consented for use in biomedical research at the European Bioinformatics Institute Justin Paschall Team Leader Genetic Variation / EGA ! European Genome-phenome
More informationGroundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
More informationGenetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association
6 Genetic testing The difference diagnostics can make The British In Vitro Diagnostics Association Genetic INTRODUCTION testing The Department of Health published Our Inheritance, Our Future - Realising
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationDelivering the power of the world s most successful genomics platform
Delivering the power of the world s most successful genomics platform NextCODE Health is bringing the full power of the world s largest and most successful genomics platform to everyday clinical care NextCODE
More informationMolecular Biotechnology Master s Degree Program
> APPLIED LIFE SCIENCES Master s Degree Program: > FULL TIME Molecular Biotechnology Master s Degree Program www.fh-campuswien.ac.at My Occupational Future. Your Career Opportunities Biotechnology is one
More informationThe 100,000 genomes project
The 100,000 genomes project Tim Hubbard @timjph Genomics England King s College London, King s Health Partners Wellcome Trust Sanger Institute ClinGen / Decipher Washington DC, 26 th May 2015 The 100,000
More informationTHE LINCOLN INSTITUTE OF HEALTH
THE LINCOLN INSTITUTE OF HEALTH Background The Chair in the Care of the Older Person will be part of the new Lincoln Institute of Health, a cross disciplinary research collaboration linking schools, colleges
More informationBIOINF 525 Winter 2016 Foundations of Bioinformatics and Systems Biology http://tinyurl.com/bioinf525-w16
Course Director: Dr. Barry Grant (DCM&B, bjgrant@med.umich.edu) Description: This is a three module course covering (1) Foundations of Bioinformatics, (2) Statistics in Bioinformatics, and (3) Systems
More informationSequencing and microarrays for genome analysis: complementary rather than competing?
Sequencing and microarrays for genome analysis: complementary rather than competing? Simon Hughes, Richard Capper, Sandra Lam and Nicole Sparkes Introduction The human genome is comprised of more than
More informationHLA-Cw*0602 associates with a twofold higher prevalence. of positive streptococcal throat swab at the onset of
1 HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study Lotus Mallbris, MD, PhD, Katarina Wolk, MD, Fabio Sánchez
More informationThe NeurOmics team at a recent project meeting
Introduction Welcome to the NeurOmics project newsletter. This is the second edition and comes after the project has been underway for just over a year. This means that whilst we still have lots of work
More informationThe Healing Power of Data
The Healing Power of Data The Healing Power of Data A Message from the Dean and Vice President for Health Sciences Imagine living in a world in which: a mobile device predicts when you are at high risk
More informationINSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance
A. Bernheim Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance OVER-MyR is funded by the European Commission within its FP7 specific
More informationBig data, e health and the Farr Institute
Big data, e health and the Farr Institute Liam Smeeth London School of Hygiene and Tropical Medicine Thanks to: Harry Hemingway, Emily Herrett, Harriet Forbes, Ian Douglas, Krishnan Bhaskaran, Tjeerd van
More informationI. Overviews...3. Year 2010 in review, Director of FIMM... 3. Views from the former and current Chair of the Board... 5. II. FIMM Launch Event...
ANNUAL REPORT 2010 Contents I. Overviews...3 Year 2010 in review, Director of... 3 Views from the former and current Chair of the Board... 5 II. Launch Event... 6 III. How is the Nordic EMBL Partnership
More informationPersonalized medicine in China s healthcare system
Personalized medicine in China s healthcare system Jingmin Kan, Sam Linsen Netherlands office for Science and Technology, Guangzhou and Shanghai, China Content PERSONALIZED MEDICINE 2 FOCUS AT THE INDIVIDUAL
More informationThe University of Texas Health Science Center at San Antonio Tobacco Funds Budget Fiscal Year Ending August 31, 2015
Permanent Health Funds for Higher Education (Fund 810) Permanent Health Funds will be assigned to schools to support health education, research programs, and infrastructure operations. Strategy F.1.2.,
More informationGenetic diagnostics the gateway to personalized medicine
Micronova 20.11.2012 Genetic diagnostics the gateway to personalized medicine Kristiina Assoc. professor, Director of Genetic Department HUSLAB, Helsinki University Central Hospital The Human Genome Packed
More informationThe. for DUKE MEDICINE. Duke University School of Medicine. People
The for DUKE MEDICINE Decades of hard work by dedicated physicians and scientists, along with capable and often inspired leadership, have placed the Duke School of Medicine among the nation s best. Now,
More informationAttacking the Biobank Bottleneck
Attacking the Biobank Bottleneck Professor Jan-Eric Litton BBMRI-ERIC BBMRI-ERIC Big Data meets research biobanking Big data is high-volume, high-velocity and highvariety information assets that demand
More informationMaster of Physician Assistant Studies Course Descriptions for Year I
FALL TERM COURSES: Master of Physician Assistant Studies Course Descriptions for Year I PHAC 7230 Fundamentals in Pharmacology for Health Care I Credit Hrs: 3 This course will build on foundational knowledge
More information2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
More informationPolicy statement. Stem cell research
Policy statement Stem cell research Introduction For some people who survive a heart attack, the damage to their heart muscle can lead to debilitating heart failure, for which there is no cure. Nearly
More informationThe M.U.R.D.O.C.K. Study
1 The M.U.R.D.O.C.K. Study Measurement to Understand Reclassification of Disease Of Cabarrus/Kannapolis Jessica Tenenbaum, PhD and many, many others 2 MURDOCK Study Measurement to Understand the Reclassification
More informationInternational Conference of the Korean Society for Molecular and Cellular Biology
International Conference of the Korean Society for Molecular and Cellular Biology Oct. 21 (Tue) ~ 23 (Thu), 2014 Korean Society for Molecular and Cellular Biology www.visitkorea.or.kr www.ksmcb.or.kr October
More informationChildren and Families Commission 714-834-5186 (office) 714-390-9567 (Cell) 949-824-6455
FOR IMMEDIATE RELEASE December 13, 2012 CONTACT: Kelly Pijl Tom Vasich Children and Families Commission UC Irvine 714-834-5186 (office) 714-390-9567 (Cell) 949-824-6455 Kelly.Pijl@cfcoc.ocgov.com tmvasich@uci.edu
More informationTranslational research facilitating experimental medicine in dementia in the UK
Translational research facilitating experimental medicine in dementia in the UK Simon Lovestone Director Biomedical Research Unit for dementia at Maudsley and King s Route Map for Dementia Research June
More informationOpenMedicine Foundation (OMF)
Scientific Advisory Board Director Ronald Davis, Ph.D. Genome Technology Center Paul Berg, PhD Molecular Genetics Mario Capecchi, Ph.D Genetics & Immunology University of Utah Mark Davis, Ph.D. Immunology
More informationPatient Centricity and the Changing Landscape of Healthcare
Patient Centricity and the Changing Landscape of Healthcare Andrea Cotter Director Healthcare Marketing IBM Corporation IBM Healthcare and Life Sciences Patient Centricity and the Changing Landscape of
More informationJust the Facts: A Basic Introduction to the Science Underlying NCBI Resources
1 of 8 11/7/2004 11:00 AM National Center for Biotechnology Information About NCBI NCBI at a Glance A Science Primer Human Genome Resources Model Organisms Guide Outreach and Education Databases and Tools
More informationObtaining Funding in Clinical Research
Obtaining Funding in Clinical Research Ellen Seely, MD Director of Clinical Research Endocrinology, Diabetes and Hypertension Division Vice Chair, Faculty Development, Department of Medicine Brigham and
More informationBig Data in Biobanking towards targeted medicine
Big Data in Biobanking towards targeted medicine Ronald Stolk Professor Clinical Epidemiology, UMCG Board member Parelsnoer Institute Chief Scientific Officer LifeLines What is a biobank? Systematic collection
More informationRisk factors for and consequences of being sickness absent/disability pensioned: a prospective twin cohort study
Updated by Pia Svedberg 26 September2014 1 / 5 Department of Clinical Neuroscience Division of Insurance Medicine Risk factors for and consequences of being sickness absent/disability pensioned: a prospective
More informationThe role of big data in medicine
The role of big data in medicine November 2015 Technology is revolutionizing our understanding and treatment of disease, says the founding director of the Icahn Institute for Genomics and Multiscale Biology
More informationElectronic Medical Records and Genomics: Possibilities, Realities, Ethical Issues to Consider
Electronic Medical Records and Genomics: Possibilities, Realities, Ethical Issues to Consider Daniel Masys, M.D. Affiliate Professor Biomedical and Health Informatics University of Washington, Seattle
More informationCAMPAIGN: Transforming MEDICINE Beyond IMAGINATION
Our CAMPAIGN: Transforming MEDICINE Beyond IMAGINATION The School of Medicine Research Building: Health Sciences Facility III A MESSAGE from DEAN REECE Consider for a moment this question what shapes the
More informationValidation and Replication
Validation and Replication Overview Definitions of validation and replication Difficulties and limitations Working examples from our group and others Why? False positive results still occur. even after
More informationHow To Understand The Relationship Between Genetics And Environment
Different Pathomechanisms for Asthma and Allergies (NEJM 363:121ff) Genetics of Complex Diseases Unraveled by Combining GWAS and Metabolomics (Nature Genetics 42:137. PLoS Genetics 4:1) Disease Management
More informationNEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER
Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed
More informationTranslational research infrastructure in Neurosciences 15.06.2011/Bruxelles
ITMO Neurosciences, sciences cognitives, neurologie, psychiatrie Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Technologie pour la santé 1 NEUROSCIENCE MEDICAL CHALLENGES
More informationWhat does the AHSC mean for you?
> > > > > > > > > > > > > > > > > > > > What does the AHSC mean for you? Our vision for the UK s first Academic Health Science Centre a mini-guide for patients Quicker access to new medicines and new treatments
More informationIntegration of Genetic and Familial Data into. Electronic Medical Records and Healthcare Processes
Integration of Genetic and Familial Data into Electronic Medical Records and Healthcare Processes By Thomas Kmiecik and Dale Sanders February 2, 2009 Introduction Although our health is certainly impacted
More informationResearch Strategy 2012 2020
Research Strategy 2012 2020 Foreword Acknowledgements We are particularly indebted to Professor David Neal and Professor Michael Olson for their expert assessment of the trends, gaps and bottlenecks in
More informationPrecision Medicine: the importance of correctly matching the tool to the task
Precision Medicine: the importance of correctly matching the tool to the task by Professor James A. Timmons PhD, King s College London, UK This year, on April 16th the Personalized Medicine World Conference
More informationSymposium on Health Informatics
Symposium on Health Informatics Hosted by the Faculty of Pharmaceutical Sciences and Faculty of Medicine Tuesday, April 5, 2016 8:30 a.m. 5:30 p.m. Life Sciences Institute, LSC3 2350 Health Sciences Mall,
More informationLeading Genomics. Diagnostic. Discove. Collab. harma. Shanghai Cambridge, MA Reykjavik
Leading Genomics Diagnostic harma Discove Collab Shanghai Cambridge, MA Reykjavik Global leadership for using the genome to create better medicine WuXi NextCODE provides a uniquely proven and integrated
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationMediSapiens Ltd. Bio-IT solutions for improving cancer patient care. Because data is not knowledge. 19th of March 2015
19th of March 2015 MediSapiens Ltd Because data is not knowledge Bio-IT solutions for improving cancer patient care Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd Copyright 2015 MediSapiens Ltd. All
More informationEMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
More informationVision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision
Vision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision Medicine Initiative: Building a Large U.S. Research Cohort
More informationYou re Invited About Us Distinctions Education Executive Education. Graduate Training Technology Contact Us
You re Invited About Us Distinctions Education Executive Education Graduate Training Technology Contact Us You re Invited Cleveland Clinic Global Physician Associate Program You re Invited Cleveland Clinic
More informationPersonalised Healthcare Frequently Asked Questions
Personalised Healthcare Frequently Asked Questions Foreword In one sense, personalised healthcare is nothing new. It is what doctors have aimed to provide for their patients through the exercise of their
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationHouston Cancer Institute
Houston Cancer Institute A personal path to healing Memorial-West Houston Katy Northwest Houston Southeast Houston Sugar Land Convenience for Patients State of the Art Therapies and Diagnosis Real Support
More informationAccelerate genomic breakthroughs in microbiology. Gain deeper insights with powerful bioinformatic tools.
Accelerate genomic breakthroughs in microbiology. Gain deeper insights with powerful bioinformatic tools. Empowering microbial genomics. Extensive methods. Expansive possibilities. In microbiome studies
More informationGriffith University - Case for Support. Mesothelioma Research Program
Griffith University - Case for Support Mesothelioma Research Program Professor Lyn Griffiths Director, Dean, Research and Director, Genomics Research Centre (GHI) Established in 2007. Integrated health
More informationIntegrated Biomedical and Clinical Research Informatics for Translational Medicine and Therapeutics
Integrated Biomedical and Clinical Research Informatics for Translational Medicine and Therapeutics J. Richard Landis, PhD Robert M. Curley, MS Gregg Fromell, MD Center for Clinical Epidemiology and Biostatistics
More informationGENOMICS: REINVIGORATING THE FIELD OF PSYCHIATRIC RESEARCH
Office of Communications www.broadinstitute.org T 617-714-7151 communications@broadinstitute.org 7 Cambridge Center, Cambridge, MA 02142 GENOMICS: REINVIGORATING THE FIELD OF PSYCHIATRIC RESEARCH For decades,
More informationCentre for Biomarker Research in Medicine. COMET Competence Centre for Excellent Technologies
Centre for Biomarker Research in Medicine COMET Competence Centre for Excellent Technologies Why Biomarker Research? early diagnosis, often before manifestation identification of at-risk patients for new
More informationTHE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS
Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.
More informationCenter for Causal Discovery (CCD) of Biomedical Knowledge from Big Data University of Pittsburgh Carnegie Mellon University Pittsburgh Supercomputing
Center for Causal Discovery (CCD) of Biomedical Knowledge from Big Data University of Pittsburgh Carnegie Mellon University Pittsburgh Supercomputing Center Yale University PIs: Ivet Bahar, Jeremy Berg,
More information